Ocaliva Lawsuit 2026

Ocaliva was supposed to protect your liver. Instead, for many, it destroyed it.

 Ocaliva was sold as a treatment for primary biliary cholangitis, a chronic disease that damages the bile ducts in the liver. It came to market with promise. It left the market under a cloud of serious liver injury, transplant, and death.

By late 2025, the FDA had withdrawn approval of Ocaliva after concluding the postmarketing evidence showed excess liver transplants and deaths, and did not verify the clinical benefit the company needed to prove. Intercept then pulled the drug from the United States market.

Every drug case starts with a simple question. Did the medicine hurt people in a way the company should have understood, warned about, and acted on sooner? With Ocaliva, the answer looks more and more like yes.

The safety warnings came in waves. First, the FDA warned about serious liver injury tied to incorrect dosing in 2017. Then it added a boxed warning in 2018. Then it restricted the drug in advanced cirrhosis in 2021. Then it said in late 2024 that serious liver injury was being seen even in patients without cirrhosis. By then, the warning signs had piled up like storm clouds over a beach house in August.

How many warnings does a drug company get before it has to stop pretending the problem is manageable and admit the drug itself is the problem?

This page is for people who want the straight story. What Ocaliva is. Why are people looking at lawsuits? What injuries matter? Who may qualify? What evidence helps? And what happens next if you or someone you love gets badly hurt after taking this drug? We are going to keep it simple, but not watered down.

What Ocaliva Was Supposed to Do

Ocaliva is the brand name for obeticholic acid. The FDA approved it in 2016 for adults with primary biliary cholangitis, usually called PBC, who did not respond adequately to ursodeoxycholic acid or could not tolerate it. PBC is a long-term liver disease. It slowly damages the small bile ducts, disrupts bile flow, and can lead to scarring, cirrhosis, liver failure, transplant, or death. That disease is serious enough on its own. Patients do not need a drug that increases the likelihood of the same endpoint.

That is what makes the Ocaliva story so disturbing. This was not a cosmetic or weight loss drug. This was not a medicine people took for convenience. It was prescribed to people with an already fragile organ system. The manufacturer knew full well that the patient population was vulnerable. The regulators knew it, by the way.  That is why the safety profile mattered so much from day one. When you give a liver drug to liver patients, there is no room for sloppiness.

Why Victims Are Suing Over Ocaliva

The heart of an Ocaliva lawsuit is not complicated. We contend that Intercept sold and kept selling a drug that it knew was linked to worsening liver function, hepatic decompensation, liver failure, transplant, and death. The warnings lagged behind the danger. That is a classic failure to warn case, with a possible second layer involving whether the drug should have remained on the market as long as it did.

The company would like this to be framed as a problem of disease progression or dosing confusion. The real truth is that this will be a viable defense in some cases.  But it will not work in all of them, and probably not most.

In 2021, the FDA restricted Ocaliva in PBC patients with advanced cirrhosis because it could cause serious harm, including liver failure. Then, in December 2024, the FDA went further and said serious liver injury was being observed in patients without cirrhosis, including cases involving transplant and liver-related death.

Drug companies often hide behind the idea that the sickest patients were always going to do poorly. But if patients without cirrhosis were also showing serious liver injury signals, the defense gets thinner. The drug starts to look less like a risky option for desperate patients and more like a medication whose benefit-risk picture would leave few to ever consider the drug.

The Regulatory Timeline Helps Make the Case

In September 2017, the FDA warned that some patients with moderate to severe liver impairment were being dosed too often, which increased the risk of serious liver injury and death. In February 2018, the agency added a boxed warning, its strongest label warning, emphasizing correct dosing for patients with more severe liver disease.

In May 2021, the FDA restricted the use of the drug in patients with advanced cirrhosis because some patients with cirrhosis who took Ocaliva developed liver failure, sometimes requiring transplant. Then, in December 2024, the agency reported serious liver injury in patients without cirrhosis based on postmarketing clinical trial data. Finally, by late 2025, the FDA finally withdrew approval after finding that the postmarketing trial failed to verify clinical benefit and showed excess liver transplants and deaths in Ocaliva-treated PBC patients with early-stage disease at baseline.

When a case gets to a jury, that timeline matters, and a good Ocaliva lawyer will have fun crafting the timeline in opening statements. Juries understand a warning.

What Injuries Make the Strongest Ocaliva Lawsuits?

Not every bad experience with a medicine turns into a viable product liability lawsuit. The strongest Ocaliva cases from a damages standpoint will be acute liver injury, hepatic decompensation, liver failure, transplant evaluation, actual transplant, prolonged hospitalization, or death. Those are the injuries that fit what you would expect given what we now know.

A good plaintiff case usually has a timeline that shows the patient started Ocaliva, then experienced a meaningful liver decline that cannot be explained away by some of the defenses we will talk about in a few moments. That may include rising bilirubin, worsening liver enzymes, jaundice, ascites, confusion, bleeding, swelling, black stools, severe abdominal pain, less frequent urination, or the kind of mental status changes doctors associate with a failing liver.

The pain and suffering testimony in cases like this is very important.  Families describe it in plain English. Mom was tired all the time. Dad could not think clearly. The skin and eyes turned yellow. The hospitalizations started coming closer together. Those human details reveal the human side of the injury and often align with the lab record.

The most valuable claims will usually involve one or more of these situations. A patient without cirrhosis who went into serious liver decline after Ocaliva. A patient with advanced cirrhosis who should never have stayed on the drug once the warnings tightened. A patient whose doctor kept prescribing it while the liver kept getting worse. A family that lost someone to liver failure after Ocaliva stayed in the treatment plan longer than it should have.

Why Could Ocaliva Lawsuits Be Especially Strong

Let’s start with the weakness:  the patients already had liver disease. Defense lawyers usually love that fact pattern. They will say the disease caused the injury, not the drug. They will argue that the patient was sick before the first tablet. They certainly will say, because it is correct, PBC itself is progressive and unforgiving. All that is true as far as it goes. It just does not end the analysis.

Plaintiffs do not need to prove the patient had a perfect liver before Ocaliva. They need to show that Ocaliva caused or materially worsened the decline. That is the legal standard, and it is a very different question. If the baseline was stable and the trajectory changed after the drug, that is your damages.  An even stronger case would be a patient who never had cirrhosis and still ended up on a transplant path.

So, for our lawyers to assess the quality of your case, the medical records are the key.  The patient’s baseline, dosing, lap trends, and doctors’ notes help paint the picture.  A good Ocaliva claim is built like a timeline with no gaps. You want to show where the patient started, what happened after the drug was introduced, which symptoms appeared, what the tests showed, what decisions the doctors made, and how the case ended.

Who Qualifies for an Ocaliva Lawsuit?

Most law firms screening Ocaliva lawsuits are looking for a straightforward set of facts.  They want a victim who was prescribed Ocaliva for primary biliary cholangitis. After starting the medication, the person suffered serious liver-related harm. That harm might include liver injury requiring hospitalization, hepatic decompensation, transplant evaluation, actual transplant, or, in extreme cases, death. In the latter, the families of people who died may have wrongful death and survival action claims.

Some cases may also be strong because of who got the drug and when. If a patient had advanced cirrhosis after the label restrictions and still remained on Ocaliva, that could be the makings of a viable claim. If a patient continued on the drug despite clear evidence of worsening liver disease, that similarly has the makings of a viable claim.

The statute of limitations is also something to get in front of before you lose your rights to bring a claim. These deadlines to sue vary by state, often ranging from 1 to 6 years, and the triggering date may depend on when the injury occurred, when it was diagnosed, when the patient died, or when the connection to Ocaliva should reasonably have been discovered. The solution is to talk to a lawyer sooner rather than later to make sure you understand what deadlines apply to you.

What Evidence Helps Most

We touched on this a bit above.  The medical records are key in any Ocaliva lawsuit.  Our attorneys start with prescription records and pharmacy records showing Ocaliva use, dosage, start date, refill history, and prescribing doctor. Then gather the liver function labs from before, during, and after treatment. Add hospital records, imaging, specialist notes, transplant evaluations, pathology, and discharge summaries. If this is a wrongful death lawsuit, you also want the death certificate and any coroner or autopsy materials if they exist.

The best records for developing a viable lawsuit will show progression. They show what the patient looked like before Ocaliva and after Ocaliva. Again, that is what you are compensated for — the difference between what you are and what you would have been without Ocaliva.

Do not underestimate the value of ordinary details either. Notes from family members can help establish the timing of symptoms. Employer records can help show lost wages or diminished ability to work.  A transplant changes life in obvious ways, but even short of a transplant, serious liver injury can affect energy, cognition, sleep, appetite, mood, and the ability to function. You want to give the jury the whole picture, not just the lab numbers.

What Compensation May Be Available

There are no public Ocaliva settlements or even trials.  We are in the early rounds of this.  There is no established Ocaliva MDL or class action lawsuit as of early 2026. We are in the investigation and intake phase.

That said, the damages theory is obvious. If Ocaliva caused or worsened serious liver injury, plaintiffs can pursue past and future medical expenses, hospitalization costs, transplant and transplant follow-up costs, lost wages, diminished earning capacity, pain and suffering, emotional distress, and loss of enjoyment of life. In death cases, families may also seek funeral costs, loss of financial support, and loss of companionship under the applicable wrongful death statute. If the corporate conduct looks reckless enough once discovery starts, punitive damages could become part of the conversation.

So how much is a successful Ocaliva settlement expected to be?  Our attorneys are quick to make settlement projects early in the litigation.  But this is just too early to guess an Ocaliva settlement yet.  We need to see how the facts develop first.

The Bottom Line on the Ocaliva Lawsuit

As we have been saying, our lawyers think the case has jury appeal. This is the kind of case that makes jurors angry once they put the pieces of the puzzle together. A liver drug goes on the market for liver patients. Serious liver warnings start early. The warnings keep getting stronger. The agency later says the problem reaches patients without cirrhosis. Then the drug gets pulled because the benefit was not verified, and the trial showed excess liver transplants and deaths. That is a rough story for any manufacturer to carry into a courtroom.

Our view is simple. If Ocaliva was part of the reason your liver function crashed, you should have that evaluated now, not six months from now. If a loved one died after taking Ocaliva and the medical story never made full sense, you should move forward quickly and find out if you have a claim.  A lot of dangerous drug cases turn on what happened in a narrow window. Miss the records or the deadline, and the case can die before it starts.

Ocaliva is off the market. That part is over. The harder question is whether those hurt by it will receive answers and compensation. That part is just beginning.

Contact Us About Filing an Ocaliva Liver Injury Lawsuit

Our lawyers are reviewing cases across all 50 states, assessing claims on a case-by-case basis to help victims pursue fair compensation for their suffering. If you believe your condition could have been made much worse by Ocaliva, reach out for a consultation to determine your eligibility. Contact our office today for a free consultation at 800-553-8082 or get a free online consultation.